SCHEMBL4834937

SCHEMBL4834937

COC(=O)c1c(C)cccc1CO[C@@H]1CCC[C@H](OCc2coc(-c3ccc(F)cc3)n2)C1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.44
PPARA Q07869 5/20 0.41
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38
KMT2A Q03164 1/20 0.38
PPARG P37231 4/20 0.35
EPHX2 P34913 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
FFAR1 O14842 1/20 0.33
ACKR3 P25106 1/20 0.33
KCNJ5 P48544 1/20 0.33
KCNJ3 P48549 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14106685 1.00 HPGD (0.44) HPGDPPARALMNAGAATSHR
SCHEMBL4832091 0.93 HPGD (0.44) HPGDPPARALMNAGAATSHR
SCHEMBL14106700 0.93 PPARA (0.41) HPGDPPARAPPARGEPHX2HDAC1
SCHEMBL14106701 0.93 PPARA (0.41) HPGDPPARAPPARGEPHX2HDAC1
SCHEMBL14106689 0.92 PPARA (0.39) PPARAPPARGEPHX2FFAR1KCNJ5
SCHEMBL4829910 0.92 PPARA (0.39) PPARAPPARGEPHX2FFAR1KCNJ5
SCHEMBL13154156 0.92 HPGD (0.41) HPGDPPARALMNAGAATSHR
SCHEMBL4830102 0.91 HPGD (0.43) HPGDPPARALMNAGAATSHR
SCHEMBL6477666 0.91 HPGD (0.43) HPGDPPARALMNAGAATSHR
SCHEMBL4830119 0.91 HPGD (0.43) HPGDPPARALMNAGAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803950-B2 Method for the production of diarylcycloalkyl derivatives SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-09-28 US disclosed
US-7803950-B2 Method for the production of diarylcycloalkyl derivatives SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-09-28 US disclosed
US-7399777-B2 Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-07-15 US disclosed
US-20080051583-A1 NOVEL INTERMEDIATE COMPOUNDS USEFUL IN THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-28 US disclosed
US-20080051583-A1 NOVEL INTERMEDIATE COMPOUNDS USEFUL IN THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-28 US disclosed
US-20070197614-A1 METHOD FOR THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-23 US disclosed
US-20070197614-A1 METHOD FOR THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-23 US disclosed
US-20050267177-A1 Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-12-01 US disclosed
US-6884812-B2 Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-04-26 US disclosed
US-20040122069-A1 Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-06-24 US disclosed
US-6624185-B2 Drugs at least one lipid- or triglyceride-lowering active compound; and carriers for lipid metabolism AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-09-23 US disclosed
US-20030144332-A1 Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2003-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144332-A1 Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals PNLIP, LIPC, APOB HPGD 690/4885PPARA 383/4885LMNA 1312/4885
US-20040122069-A1 Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals PNLIP, LIPC, APOB HPGD 660/4885PPARA 365/4885LMNA 1215/4885
US-20050267177-A1 Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals PNLIP, LIPC, LIPA HPGD 626/4885PPARA 345/4885LMNA 1198/4885
US-20080051583-A1 NOVEL INTERMEDIATE COMPOUNDS USEFUL IN THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES PPARG, PPARD, PPARA HPGD 274/4885PPARA 3/4885LMNA 3228/4885
US-20070197614-A1 METHOD FOR THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES PPARA, PPARD, PPARG HPGD 670/4885PPARA 1/4885LMNA 3947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.